Teyi Pharmaceutical Group (002728.SZ): Glucosamine sulfate capsules have obtained a drug registration certificate.
Tefi Pharmaceutical (002728.SZ) announced that its wholly-owned subsidiary, Hainan Haili Pharmaceutical Co., Ltd. (referred to as "Haili Pharmaceutical"), recently received the "Drug Registration Certificate" for glucosamine sulfate capsules issued by the National Medical Products Administration. Glucosamine sulfate capsules are used for primary and secondary osteoarthritis.
Teyi Pharmaceutical Group (002728.SZ) announced that its wholly-owned subsidiary Hainan Haili Pharmaceutical Co., Ltd. (referred to as "Haili Pharmaceutical") recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for glucosamine sulfate capsules. Glucosamine sulfate capsules are suitable for primary and secondary osteoarthritis.
Related Articles

Zhixiang Jintai (688443.SH) plans to launch a restricted stock incentive plan in 2026.

Wuchan Zhongda Group plans to repurchase shares worth 200 million to 400 million yuan.

WELLE Environmental Group (300190.SZ) has won the bidding for a sewage treatment project worth 44.88 million yuan.
Zhixiang Jintai (688443.SH) plans to launch a restricted stock incentive plan in 2026.

Wuchan Zhongda Group plans to repurchase shares worth 200 million to 400 million yuan.

WELLE Environmental Group (300190.SZ) has won the bidding for a sewage treatment project worth 44.88 million yuan.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


